Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Capital Expenditures: 2018-2025

Historic Capital Expenditures for Arcturus Therapeutics Holdings (ARCT) over the last 6 years, with Sep 2025 value amounting to $181,000.

  • Arcturus Therapeutics Holdings' Capital Expenditures rose 126.25% to $181,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $726,000, marking a year-over-year decrease of 52.33%. This contributed to the annual value of $648,000 for FY2024, which is 77.66% down from last year.
  • According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' Capital Expenditures is $181,000, which was up 32.12% from $137,000 recorded in Q1 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Capital Expenditures ranged from a high of $3.8 million in Q4 2022 and a low of $23,000 during Q2 2022.
  • Its 3-year average for Capital Expenditures is $429,667, with a median of $328,000 in 2024.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Capital Expenditures plummeted by 91.90% in 2022, and later soared by 1,439.13% in 2023.
  • Arcturus Therapeutics Holdings' Capital Expenditures (Quarterly) stood at $1.1 million in 2021, then soared by 240.52% to $3.8 million in 2022, then slumped by 77.02% to $875,000 in 2023, then slumped by 91.85% to $80,000 in 2024, then skyrocketed by 126.25% to $181,000 in 2025.
  • Its Capital Expenditures was $181,000 in Q3 2025, compared to $137,000 in Q1 2025 and $80,000 in Q3 2024.